3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Large B-Cell, Diffuse
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraganglioma, Extra-Adrenal
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Osteosarcoma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Gynecological Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Diseases
1
Carcinoma
1
Breast Neoplasms
1
Breast Neoplasm Female
1
Interventions
Oxaliplatin
146
Fluorouracil
137
Capecitabine
122
Leucovorin
106
Irinotecan
85
Radiotherapy
67
Bevacizumab
64
Cetuximab
46
Folfox protocol
28
Surgical Procedures, Operative
23
Radiation
23
Drug Therapy
22
Panitumumab
19
XELOX
18
Chemotherapy, Adjuvant
15
Neoadjuvant Therapy
14
Radiotherapy, Intensity-Modulated
13
Chemoradiotherapy
13
Magnetic Resonance Spectroscopy
11
regorafenib
10
Nivolumab
10
Floxuridine
10
sintilimab
8
raltitrexed
8
Specimen Handling
8
IFL protocol
8
Celecoxib
8
Biopsy
8
trifluridine tipiracil drug combination
7
tislelizumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Rectal Neoplasms
×
penpulimab
×
Clear all
NCT05576480
2025-08-28
SPARC
Ruijin Hospital
Phase 2
Recruiting
55 enrolled